LKFT — Lakefront Biotherapeutics NV
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1421876 ·
Belgium
Last close
$28.37
Market Cap
—
52W High
$33.12
52W Low
$26.42
ADV30
186,370
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 6,481,000 | 1,682,000 | -63,703,000 | 14,492,000 | 3,372,429,000 | 66,805,000 | 119,060,000 |
| Dec 2025 | 900,822,000 | 900,367,000 | 758,798,000 | 782,146,000 | 3,406,518,000 | 87,868,000 | 170,650,000 |
| Sep 2025 | 71,161,000 | 60,315,000 | -41,672,000 | -202,111,000 | 3,511,914,000 | 64,458,000 | 1,064,951,000 |
| Jun 2025 | 65,288,000 | 60,582,000 | -57,027,000 | -105,748,000 | 3,818,224,000 | 71,669,000 | 1,174,405,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-301,599,000
Investing CF
$265,566,000
Financing CF
$-2,772,000
CapEx
$-8,732,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.11
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$228,331,000
Inventory
$17,693,000
Receivables
$54,034,000
ST Investments
$2,915,435,000
EBIT TTM
$398,093,000
Pretax Income TTM
$471,194,000
Interest Exp TTM
$792,000
Analysts
2
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,112,248,000 | 501,391,000 | 320,884,000 | 3,406,518,000 | 170,650,000 | — | -257,456,000 |
| Dec 2024 | 275,649,000 | -188,338,000 | 74,082,000 | 4,135,719,000 | 1,238,780,000 | — | -320,026,000 |
| Dec 2023 | 239,724,000 | -88,263,000 | 211,697,000 | 4,357,396,000 | 1,561,830,000 | — | -405,970,000 |
| Dec 2022 | 241,249,000 | -131,057,000 | -217,991,000 | 4,734,351,000 | 2,208,325,000 | — | -500,544,000 |
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $27.50 · spot: $28.37 · call volume: 3 · put volume: 1
Expected Move to 2027-01-15:
±$5.30
(18.68%) —
implied range
$23.07 –
$33.67
· ATM straddle on $27.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $991.62B | $1112.00 | — |
| JNJ | JOHNSON & JOHNSON | $563.77B | $234.20 | — |
| ABBV | AbbVie Inc. | $390.87B | $221.23 | — |
| NVS | NOVARTIS AG | $287.89B | $150.88 | — |
| MRK | Merck & Co., Inc. | $285.12B | $115.44 | — |
News headlines (Yahoo Finance, 1h cache)
Acquisition of Own Shares
2026-06-16 20:01 · Yahoo
Lakefront Biotherapeutics (ENXTAM:LKFT) Stock After Recent Gains Still A Recovery Opportunity?
2026-06-14 02:11 · Yahoo
Lakefront Announces Initiation of €50 Million Stock Repurchase Program
2026-06-09 20:01 · Yahoo
Lakefront Appoints Eric Hedrick, MD, as Chief Medical Officer
2026-06-08 20:01 · Yahoo
Gilead Sciences (GILD), Lakefront Biotherapeutics Acquire Ouro Medicines to Advance Autoimmune Pipeline
2026-06-07 04:39 · Yahoo
Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
2026-06-04 20:15 · Yahoo
Lakefront Receives Transparency Notification from Bank of America
2026-05-26 20:01 · Yahoo
Lakefront Biotherapeutics NV (AMS:LKFT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
2026-05-10 06:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.